medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2021, Number 2

<< Back Next >>

Rev Med UAS 2021; 11 (2)

Atropine 0.01% as a treatment for one year to decrease the progression of myopia in pediatrics

Valdez-Radke AS, Acuña-Maldonado R, Cardona-Estrada C, Romo-García E

Language: Spanish
References: 12
Page: 107-114
PDF size: 349.26 Kb.


ABSTRACT

Objective: To demonstrate the decrease in the progression of myopia in pediatric patients 5 to 14 years of age with the use of 0.01% atropine. Material and methods: A total of 28 patients were recruited between 5-14 years of age, with myopia ≥-1.50 D and astigmatism ≥0.50, a dilution of atropine 0.01% was applied for one year, it was prepared individually and a refraction study was performed under cycloplegia every 4 months. Results: 4 measurements were taken into account, at the beginning of the treatment, at 4, 8, 12 months of follow-up, finding an initial refraction of -4.38 ± 0.56 D, -4.69 ± 0.25 D, -4.64 ± 0.30 and -4.95 respectively resulted with a statistically significant trend (p = 0.05). Conclusions: A reduction in the progression of myopia of -0.58 D was demonstrated in the population studied with 0.01% atropine for one year.


REFERENCES

  1. Kniestedt C, Stamper RL. Visual acuity andits measurement. Ophtlmol Clin N Am.

  2. 2003;16:155–70.2. Bourne RRA, Stevens GA, White RA, SmithJL, Flaxman SR, Price H et al. Causes ofvision loss worldwide , 1990 – 2010 : a systematicanalysis. Lancet Glob Heal. 1:339–49.

  3. Chua W, Balakrishnan V, Chan Y, Tong L,Ling Y, Quah B, et al. Atropine for the Treatment.Am Acad Ophthalmol.2006;113(12):2285–91.

  4. Chia A, Chua WH, Cheung YB, Wong WL,Lingham A, Fong A, et al. Atropine for the Treatmentof Childhood Myopia : Safety and Efficacyof 0 . 5 %, 0 . 1 %, and 0 . 01 % Doses ( Atropinefor the Treatment of Myopia 2 ). Am Acad Ophthalmol.2011;119(2):347–54.

  5. Joachimsen L, Bo D, Gross NJ, Reich M,Stifter J, Reinhard T, et al. A Pilot Study onthe Efficacy and Safety of 0 . 01 % Atropinein German Schoolchildren with ProgressiveMyopia. Ophtalmol Ther. 2019;8(3):427–33.

  6. Yam JC, Jiang Y, Tang SM, Law AKP, ChanJJ, Wong E, et al. Low-Concentration Atropinefor Myopia Progression (LAMP) Study:A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and0.01% Atropine Eye Drops in Myopia Control.Am Acad Ophthalmol.2019;126(1):113–24.

  7. Prepas SB. Light, literacy and the absenceof ultraviolet radiation in the development ofmyopia. Medical Hypotheses.2008;70(3):635–7.

  8. Yanoff M, Duker JS. Ophtalmology. Third.Edunburg: Mosby Elsevier; 2009. 61–65 p.

  9. Diaz-Llopis M, Pinazo-Durán MD. La atropinasuperdiluida al 0,01% frena el aumentode miopía en niños-adolescentes. Un estudioa largo plazo 5 años de evolución: seguridady eficacia. Arch Soc Esp Oftalmol

  10. Fan DSP, Lam DSC, Chan CKM, Fan AH,Cheung EYY, Rao SK. Topical Atropine inRetarding Myopic Progression and AxialLength Growth in Children with Moderate toSevere Myopia : A Pilot Study. Jpn J Ophtalmol.2007;51:27–33.

  11. Fang P, Chung M, Yu H, Wu P. Preventionof Myopia Onset with 0.025% Atropine inPremyopic Children. J Ocul PharmacolTher. 2010;26(4):341–5.

  12. Sacchi M, Serafino M, Villani E, TagliabueE, Luccarelli S, Bonsignore F, et al. Efficacyof atropine 0.01% for the treatment ofchildhood myopia in European patients.Acta Ophthalmol. 2019;97(8):1136–40.




2020     |     www.medigraphic.com